Ameriprise Financial Inc. decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 38.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 144,645 shares of the company’s stock after selling 91,579 shares during the quarter. Ameriprise Financial Inc. owned about 0.17% of IDEXX Laboratories worth $22,491,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also recently made changes to their positions in IDXX. Koch Industries Inc. boosted its holdings in shares of IDEXX Laboratories by 44,533.1% during the second quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock valued at $1,391,000 after acquiring an additional 1,396,113 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of IDEXX Laboratories by 486.4% during the second quarter. Janus Henderson Group PLC now owns 1,131,902 shares of the company’s stock valued at $182,711,000 after acquiring an additional 938,888 shares during the period. BlackRock Inc. boosted its holdings in shares of IDEXX Laboratories by 10.5% during the second quarter. BlackRock Inc. now owns 7,100,374 shares of the company’s stock valued at $1,146,142,000 after acquiring an additional 673,347 shares during the period. Old Mutual Global Investors UK Ltd. acquired a new position in shares of IDEXX Laboratories during the second quarter valued at $83,723,000. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in shares of IDEXX Laboratories by 42.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,310,660 shares of the company’s stock valued at $211,567,000 after acquiring an additional 392,790 shares during the period. 86.80% of the stock is owned by institutional investors.
In other IDEXX Laboratories news, insider Giovani Twigge sold 2,000 shares of the company’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $156.07, for a total value of $312,140.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Jonathan W. Ayers sold 54,000 shares of the company’s stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $151.32, for a total transaction of $8,171,280.00. Following the completion of the sale, the chairman now directly owns 1,064,573 shares of the company’s stock, valued at $161,091,186.36. The disclosure for this sale can be found here. Insiders sold a total of 110,000 shares of company stock valued at $16,686,200 over the last three months. 2.77% of the stock is owned by corporate insiders.
Shares of IDEXX Laboratories, Inc. (NASDAQ IDXX) opened at $160.57 on Friday. The firm has a market cap of $13,935.81, a PE ratio of 53.80, a P/E/G ratio of 2.42 and a beta of 0.42. IDEXX Laboratories, Inc. has a 1-year low of $113.92 and a 1-year high of $173.01. The company has a debt-to-equity ratio of -12.48, a current ratio of 0.95 and a quick ratio of 0.77.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The business had revenue of $492.00 million during the quarter, compared to the consensus estimate of $492.94 million. During the same quarter in the prior year, the company posted $0.62 earnings per share. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. analysts forecast that IDEXX Laboratories, Inc. will post 3.24 EPS for the current fiscal year.
IDXX has been the subject of several analyst reports. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price target for the company in a report on Tuesday, October 24th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a report on Tuesday, October 24th. Canaccord Genuity reaffirmed a “buy” rating and issued a $180.00 price objective on shares of IDEXX Laboratories in a report on Friday, October 6th. Finally, Bank of America raised shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price objective for the company in a report on Wednesday, August 23rd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $173.67.
ILLEGAL ACTIVITY WARNING: This news story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/12/10/ameriprise-financial-inc-sells-91579-shares-of-idexx-laboratories-inc-idxx.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.